Anti-saccharification application of stigmastane mixture
By using stigmasterane mixture to inhibit the generation of AGEs in vivo, the problem of insufficient safety and absorption of anti-saccharification components in the prior art is solved, effective anti-saccharification effects are achieved, and skin health and whitening and brightening effects are improved.
Patent Information
- Application Number
- CN202410969425.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively inhibit the saccharification reaction of biological macromolecules in the body, resulting in skin health problems such as wrinkles, pigmentation and oxidative damage. At present, anti-saccharification ingredients such as carnosine and lipoic acid have insufficient safety and absorption.
Using stigmasterane mixture as an anti-saccharification component, it is used to prepare drugs, health foods, oral agents or skin topical agents with anti-saccharification effects by inhibiting the generation of the terminal product AGEs of non-enzymatic glycosylation reactions, with a concentration range of 0.00005- 10% by weight.
The stigmasterane mixture significantly reduces the AGEs content and has excellent anti-saccharification effects. It can whiten, brighten, remove yellowing, and resist aging, improve skin health. Due to its natural properties, it has high safety and fewer toxic and side effects.
Smart Images

Figure BDA0004952977160000021 
Figure BDA0004952977160000022 
Figure BDA0004952977160000131
Abstract
Description
Technical Field
[0001] The invention relates to the field of natural drug chemistry, and in particular to the anti-glycation application of a stigmasterane mixture and the application of the stigmasterane mixture in the preparation of a skin external preparation, a medicine and a health food with anti-glycation effect. Background Art
[0002] In 1912, Frenchman Louis Camille Maillard first proposed the concept of glycation reaction when describing the reaction of brown melanoidin formed when glycine and glucose were mixed and heated. Therefore, glycation reaction is also called Maillard reaction. In 1984, Brownlee first reported the phenomenon of advanced glycation end-products (AGEs) in biological macromolecules in the body. AGEs refer to free amino groups and carbonyl groups of reducing sugars in biological macromolecules such as nucleic acids, proteins, and lipids, which are generated under non-enzymatic conditions through a series of reactions such as condensation, rearrangement, cleavage, and oxidative modification. AGEs are brown in color, can undergo irreversible cross-linking reactions, are not afraid of enzyme damage, are not easily degraded, have special absorption spectra and fluorescence characteristics, can gradually accumulate in the body, and can bind to many cell membrane-specific receptors to exert biological effects.
[0003] AGEs are harmful products of uncontrolled condensation reactions in the human body. They have a very adverse effect on human health, especially skin health, mainly in the following aspects: First, sugar molecules react with protein amino groups to form glycated proteins. Collagen and elastin are the scaffolds of the skin. Once combined with sugar molecules, their properties and structures will undergo irreversible changes or even destruction, causing the skin to lose elasticity, collapse in structure, and eventually form wrinkles. Glycated proteins will also accumulate in the body. This brown substance will affect the light transmittance of the skin, making the skin look dark and dull. Secondly, accumulated AGEs can not only be directly deposited in the skin to cause pigmentation, but also can act on the receptor for advanced glycation end products (RAGE), activate melanin-related signaling pathways, upregulate the expression of related genes and the activity of tyrosinase, and promote the production of melanin, which further aggravates skin pigmentation. Finally, AGEs and free radicals will promote each other, increase oxidative pressure in the body, cause oxidative damage to the skin, and even aggravate inflammation in the body, resulting in skin problems and even a variety of health problems.
[0004] More and more studies hope to improve diseases, delay aging, and maintain youthful skin by inhibiting the glycation reaction of biological macromolecules in the body. At present, the mainstream anti-glycation ingredients include carnosine, lipoic acid, flavonoids, polyphenols, glycosides, grape seed extract, etc. They can be roughly divided into two categories: artificial synthesis and natural extraction. In terms of natural extraction, Chinese herbal extracts are the most excellent. Chinese herbal extracts themselves have natural properties, high safety, low toxicity and side effects, easy to use and absorb, and other excellent properties. They have very high research value and broad application prospects.
[0005] The stigmasterane mixture can be separated and purified from plants such as chamomile and Ailanthus altissima. The stigmasterane mixture is a mixture of stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione in a ratio of about 1:1 (by weight).
[0006] English name: Stigmasta-22-ene-3,6-dione, CAS number: 88661-99-8, molecular weight: 426.7, molecular formula: C 29 H 46 O2. The structural formula of stigmasterane-22-ene-3,6-dione is:
[0007]
[0008] 5α-stigmastan-3,6-dione English name: 5α-stigmasta-3,6-dione, CAS number: 22149-69-5, molecular weight: 428.7, molecular formula: C 29 H 48 O2. The structural formula of 5α-stigmasterane-3,6-dione is:
[0009]
[0010] The molecular weight of the stigmasterane mixture is the average molecular weight of the two: 427.7.
[0011] Wang Yuan analyzed the compound components in Croton tiglium and isolated 29 compounds from the 95% ethanol extract of its stem, including stigmasterane-22-ene-3,6-dione; Feng Yalong isolated and identified 33 compounds from the ethyl acetate part of the 80% methanol extract of Plantago, including 5α-stigmasterane-3,6-dione; Chang Xuejian isolated and identified 24 monomer compounds from the active fraction of Scutellaria baicalensis, including 5α-stigmasterane-3,6-dione. Tu Pengfei extracted and purified litchi kernels using 70% ethanol and finally identified 13 compounds, including stigmasterane-22-ene-3,6-dione and 5α-stigmasterane-3,6-dione. Although there are many papers reporting on the separation and purification of stigmasterane mixtures, none of them have studied the biological activity of stigmasterane mixtures, especially the skin care effects.
[0012] The present invention unexpectedly discovered that the stigmasterane mixture can effectively reduce the content of AGEs, the end product of non-enzymatic glycosylation reaction, and has an excellent anti-glycation effect. Summary of the invention
[0013] The invention provides an anti-glycation application of a stigmasterane mixture.
[0014] In a preferred embodiment, the stigmasterane mixture is used at a concentration of at least 0.5 mg / L, more preferably at least 1 mg / L.
[0015] In a preferred embodiment, anti-glycation is to inhibit the end products of non-enzymatic glycosylation reactions. In a preferred embodiment, anti-glycation is to inhibit the end products of glycation.
[0016] The invention also relates to the use of the stigmasterane mixture in the preparation of medicines, health foods, oral preparations or external skin preparations with anti-glycation effects.
[0017] In a preferred embodiment, the content of the stigmasterane mixture in the medicine, health food, oral preparation or external skin preparation is 0.00005-10% by weight, more preferably 0.0001-5% by weight.
[0018] In a preferred embodiment, the medicine, health food, oral agent or skin topical agent is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The anti-glycation immunofluorescence staining of the blank control group is shown (the immunofluorescence image was taken under a 20x objective field of view of a Leica inverted fluorescence microscope, blue fluorescence represents the cell nucleus signal, and red fluorescence represents the CML signal. The stronger the red, the more obvious the glycation degree).
[0021] Figure 2 The anti-glycation immunofluorescence staining of the glycation induced group is shown (the immunofluorescence image was taken under a 20x objective field of view of a Leica inverted fluorescence microscope. The blue fluorescence represents the cell nucleus signal, and the red fluorescence represents the CML signal. The stronger the red color, the more obvious the glycation degree. Compared with the blank control group, the red color in the glycation induced group became significantly stronger, indicating that the glycation induction was successful).
[0022] Figure 3 The anti-glycation immunofluorescence staining of stigmasterane mixture Example 2 is shown (the immunofluorescence image was taken under a Leica inverted fluorescence microscope with a 20x objective field of view, blue fluorescence represents the cell nucleus signal, red fluorescence represents the CML signal, and the stronger the red, the more obvious the glycation degree. Compared with the glycation-induced group, the red color was significantly weakened, indicating that stigmasterane mixture Example 2 has an anti-glycation effect).
[0023] Figure 4 The anti-glycation immunofluorescence staining of stigmasterane mixture Example 3 is shown (the immunofluorescence image was taken under a Leica inverted fluorescence microscope with a 20x objective field of view, blue fluorescence represents the cell nucleus signal, red fluorescence represents the CML signal, and the stronger the red, the more obvious the glycation degree. Compared with the glycation-induced group, the red color was significantly weakened, indicating that stigmasterane mixture Example 3 has an anti-glycation effect). DETAILED DESCRIPTION
[0024] The present invention relates to the anti-glycation effect of a stigmasterane mixture. It is the first time to find that the stigmasterane mixture can be used as an effective additive to prepare medicines, health foods, oral preparations or skin external preparations to achieve skin care effects such as whitening and brightening, yellowing removal, and anti-aging.
[0025] In order to provide a more concise description, some quantitative expressions given herein are not modified by the term "about". It should be understood that, whether or not the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value, and is also intended to refer to the approximate values of these given values that can be reasonably inferred by ordinary technicians in the field, including the approximate values of these given values caused by experimental and / or measurement conditions.
[0026] To provide a more concise description, some quantitative expressions herein are described as a range of about X amount to about Y amount. It should be understood that when describing a range, the range is not limited to the upper and lower limits described, but should include the entire range of about X amount to about Y amount or any amount therebetween.
[0027] The stigmasterane mixtures described herein may optionally be in finished packaging form. In one embodiment, the packaging is a container such as a plastic, metal or glass tube or jar containing the stigmasterane mixture. The product may additionally have packaging such as a plastic or cardboard box for storing the container. In one embodiment, the product comprises the stigmasterane mixture and has instructions for guiding the user to apply the stigmasterane mixture to the skin to treat the skin. Such instructions may be printed on the container, a label insert, or any other packaging.
[0028] As used herein, "topical application" means applying or spreading directly onto the external skin, scalp, or hair, for example, using the hands or an application device such as a wipe, roller, or spray.
[0029] As used herein, "cosmetically acceptable" means that the ingredients described by the term are suitable for use in contact with tissue (eg, skin or hair) without undue toxicity, incompatibility, instability, irritation, allergic response, or the like.
[0030] Stigmasterane mixture
[0031] The present invention relates to the anti-glycation effect of a mixture of stigmasterane compounds. In the study, it was found that the stigmasterane mixture can effectively reduce the generation of AGEs, the end product of non-enzymatic glycation reaction, and has excellent anti-glycation effect. Therefore, the stigmasterane mixture can be used as an effective additive for preparing medicines, health foods, oral preparations or skin topical preparations to achieve skin care effects such as whitening and brightening, yellowing removal, and anti-aging.
[0032] In anti-glycation applications, the stigmasterane mixture is used at a concentration of at least 0.4 mg / L, preferably at least 0.5 mg / L, and more preferably at least 1 mg / L.
[0033] In some embodiments, the stigmasterane mixture is used at a concentration of 0.5-200000 mg / L. In some embodiments, the stigmasterane mixture is used at a concentration of 1-100000 mg / L, preferably 0.5-200000 mg / L, preferably 1-100000 mg / L, more preferably 1-50000 mg / L.
[0034] Medicines, health foods, oral preparations or external preparations for skin containing stigmasterane mixtures
[0035] The stigmasterane mixture of the present invention can be used as an effective additive in medicines, health foods, oral preparations or external skin preparations.
[0036] In some embodiments, the content of the stigmasterane mixture in the medicine, health food, oral preparation or external skin preparation is 0.00005-10% by weight, more preferably 0.0001-5% by weight.
[0037] In some embodiments, the drug is selected from the group consisting of tablets, capsules, emulsions, suspensions, powders, granules, solutions, and various pharmaceutical dosage forms known in the art. Different dosages are added according to different types of dosage forms.
[0038] Health food is also called functional food. It has the function of regulating human body functions, but is not for the purpose of treating diseases, and is suitable for consumption by specific groups of people. In some embodiments, the health food can be in powder form.
[0039] In some embodiments, the skin topical agent is selected from the group consisting of: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol (cleansing foam), spray, shower gel and facial cleanser. Different amounts are added according to different types of preparations.
[0040] Skin external preparations are a general concept for all ingredients that are usually applied to the outside of the skin, such as cosmetic compositions. The cosmetic compositions may include basic cosmetics, facial makeup cosmetics, body cosmetics, hair care cosmetics, etc., and there is no particular restriction on the dosage form, which can be reasonably selected according to different purposes. The cosmetic compositions may also contain different media or matrix excipients permitted by cosmetics according to different dosage forms and purposes.
[0041] The skin topical preparation comprising the stigmasterane mixture can be topically applied to human skin and / or hair. The skin topical preparation can also include a cosmetically acceptable topical carrier, which can be about 50% by weight to about 99.99% by weight of the skin topical preparation (such as about 80% by weight to about 99% by weight of the skin topical preparation). In a preferred embodiment of the present invention, the cosmetically acceptable topical carrier comprises water. The cosmetically acceptable topical carrier may include one or more selected from wetting agents, emollients, grease, wetting agents and similar substances. In one embodiment, the cosmetically acceptable topical carrier comprises a substrate such as a nonwoven fabric or a membrane material.
[0042] Skin topical agents can be prepared into a variety of product types, including but not limited to lotions, creams, gels, sticks, sprays, ointments, cleansing liquid lotions and solid soaps, shampoos and hair conditioners, hair fixatives, pastes, foams, powders, mousses, shaving creams, wipes, patches, hydrogels, film-forming products, facial masks and skin films, films and cosmetics such as foundation and mascara. These product types can contain several types of cosmetically acceptable topical carriers, including but not limited to solutions, suspensions, emulsions (e.g., microemulsions and nanoemulsions), gels, solids and liposomes.
[0043] The topical skin preparation containing the stigmasterane mixture can be formulated as a solution. The solution generally contains an aqueous solvent or an organic solvent (e.g., about 50% to about 99.99% or about 90% to about 99% of a cosmetically acceptable aqueous solvent or organic solvent). Examples of suitable organic solvents include propylene glycol, polyethylene glycol, polypropylene glycol, glycerol, 1,2,4-butanetriol, sorbitan esters, 1,2,6-hexanetriol, ethanol, and mixtures thereof.
[0044] Skin topical preparations can be formulated into solutions containing emollients. Such skin topical preparations preferably contain from about 2% to about 50% of one or more emollients. As used herein, "emollient" refers to a substance used to prevent or alleviate dryness, for example, by preventing the loss of skin moisture through the skin. Examples of emollients include, but are not limited to, vegetable oils, mineral oils, aliphatic esters, etc.
[0045] Lotions can be prepared from such solutions.Lotions typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of one or more emollients and from about 50% to about 90% (e.g., from about 60% to about 80%) water.
[0046] Another type of product that can be formulated from a solution is a cream. Creams typically contain from about 5% to about 50% (e.g., from about 10% to about 20%) of one or more emollients and from about 45% to about 85% (e.g., from about 50% to about 75%) water.
[0047] Although it is preferred that the topical skin preparation containing the stigmasterane mixture contains water, the topical skin preparation may alternatively be anhydrous or an ointment containing no water but organic and / or silicone solvents, oils, lipids and waxes. The ointment may contain a simple base of animal or vegetable oils or semisolid hydrocarbons. The ointment may contain from about 2% to about 10% of one or more emollients and from about 0.1% to about 2% of one or more thickeners.
[0048] The topical agent for skin application can be formulated as an emulsion. If the topical carrier is an emulsion, about 1% to about 10% (e.g., about 2% to about 5%) of the topical carrier contains one or more emulsifiers. The emulsifier can be nonionic, anionic or cationic. Examples of suitable emulsifiers include those commonly identified as suitable emulsifiers in the field of personal care and cosmetic formulations.
[0049] Lotions and creams can be formulated as emulsions. Typically such lotions contain 0.5% to about 5% of one or more emulsifiers. Such creams typically contain about 1% to about 20% (e.g., about 5% to about 10%) of one or more emollients; about 20% to about 80% (e.g., 30% to about 70%) of water; and about 1% to about 10% (e.g., about 2% to about 5%) of one or more emulsifiers.
[0050] Oil-in-water and water-in-oil type single emulsion skin care preparations, such as lotions and creams, are well known in the cosmetics field and can be used in the present invention. Multiphase emulsion skin external preparations (such as water-in-oil-in-water type and oil-in-water-in-oil type) can also be used in the present invention. Generally, such single-phase emulsions or multiphase emulsions contain water, emollients and emulsifiers as their basic ingredients.
[0051] Skin topical preparations containing the stigmasterane mixture can also be formulated into gels (e.g., aqueous gels, alcoholic gels, alcohol / water gels, or oily gels using suitable gelling agents). Suitable gelling agents for aqueous gels and / or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gelling agents for oils (e.g., mineral oils) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain between about 0.1% and 5% by weight of such gelling agents.
[0052] The topical skin preparation comprising the stigmasterane mixture may also be formulated as a solid preparation (eg, a wax-based stick, a bar soap, a powder, or a wipe containing a powder).
[0053] In addition to the above-mentioned components, the external preparation for skin which can be used in the present invention may contain various other oil-soluble substances and / or water-soluble substances at levels conventionally established in its technical field for use in external preparations for skin for use on skin and hair.
[0054] The skin external preparation of the present invention may contain additional components commonly found in skin care compositions, such as emollients, skin regulators, emulsifiers, preservatives, antioxidants, fragrances, chelating agents, etc., as long as they are physically and chemically compatible with other components in the skin external preparation and do not affect the effects of the stigmasterane mixture of the present invention.
[0055] In some embodiments of the skin topical preparation of the present invention, one or more preservatives may be used. Suitable preservatives include p-hydroxyacetophenone, C1-C4 alkyl parahydroxybenzoate and phenoxyethanol. Based on the total weight of the composition, the amount of the preservative is about 0.5 to about 2 weight %, preferably about 0.5 to 1 weight %.
[0056] In one example of the skin external preparation of the present invention, one or more antioxidants can be used. Suitable antioxidants include butylated hydroxytoluene (BHT), ascorbyl palmitate (BHA), butylated hydroxyanisole, phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroguaiaretic acid, vitamin E or vitamin E derivatives, vitamin C and its derivatives, calcium pantothenate, green tea extract and mixed polyphenols, and mixtures of the above-mentioned substances. The antioxidant used is about 0.02 to 0.5 weight % of the total weight of the composition, and more preferably from about 0.002 to 0.1 weight % of the amount used.
[0057] In one example of the skin external preparation of the present invention, one or more emollients can be used to act as lubricants through their ability to remain on the skin surface or in the stratum corneum to reduce flaking and improve the appearance of the skin. Typical emollients include fatty esters, fatty alcohols, mineral oils, polyether silicone copolymers, and the like. Examples of suitable emollients include, but are not limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, Steareth-10, Oleth-8, PPG-4 lauryl ether, vitamin E acetate, lanolin, cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, hydroxystearate octyl, dimethyl polysiloxane, and combinations thereof. Cetyl alcohol, cetearyl ethylhexanoate, cetearyl alcohol, glyceryl stearate, and combinations thereof are preferred. When used, the emollient is used in an amount ranging from about 0.1 to about 30% by weight, preferably about 1 to about 30% by weight, based on the total weight of the composition.
[0058] In one example of the skin external preparation of the present invention, one or more moisturizers can be used. Moisturizers are also called humectants, which help to improve the effect of emollients, reduce flaking, remove the scales of the composition and improve the touch of the skin. Polyols can be used as moisturizers, including but not limited to glycerol, polyalkylene glycols, alkylene polyols and derivatives thereof, including butylene glycol, propylene glycol, dipropylene glycol, polyglycerol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6-hexanetriol, ethoxylated glycerol, propoxylated glycerol, and combinations thereof. When used, the amount of moisturizer is about 0.1 to about 20% by weight, preferably about 1 to about 15% by weight, based on the total weight of the composition.
[0059] In an example of the skin external preparation of the present invention, one or more emulsifiers can be used. Emulsifiers can be used within the scope of effective stabilizing amount. Preferably, based on the total weight of the composition, the emulsifier is used in an amount of about 1.0 to about 10.0 weight %, more preferably about 3.0 to about 6.0 weight %. Any emulsifier compatible with the components in the composition can be used. Suitable emulsifiers include stearic acid, cetyl alcohol, glyceryl stearate, lecithin, stearyl alcohol, Steareth-2, Steareth-20, acrylic acid (ester) class / C10-30 alkyl alcohol acrylate cross-linked polymer, and combinations thereof.
[0060] In one example of the skin external preparation of the present invention, one or more pH regulators can be used. The pH regulator useful in the skin external preparation of the present invention includes tromethamine. When used, the amount of the pH regulator based on the total weight of the composition is about 0.1 to about 2 weight %, preferably about 0.1 to about 1 weight %.
[0061] In a specific embodiment of the present invention, the skin topical agent comprises acrylates / C10-30 alkyl acrylate crosspolymer, glycerin, p-hydroxyacetophenone, glyceryl stearate and lecithin, cetearyl alcohol, cetearyl ethylhexanoate, tromethamine or a combination thereof.
[0062] Additional cosmetic active agents
[0063] In some embodiments, the topical skin preparation may also include additional cosmetic active agents. As used herein, "cosmetic active agents" are compounds (such as synthetic compounds or compounds isolated from natural sources or natural extracts) that have cosmetic or therapeutic effects on skin or hair, including but not limited to anti-acne agents, oil control agents, antimicrobial agents, anti-inflammatory agents, antifungal agents, antiparasitic agents, topical analgesics, sunscreens, photoprotectants, antioxidants, keratolytic agents, surfactants, moisturizers, nutrients, vitamins, energy enhancers, antiperspirants, astringents, deodorants, curing agents, anti-hard cuticle agents, and agents for hair and / or skin conditioning.
[0064] In one embodiment, these cosmetic actives are selected from (but not limited to): hydroxy acids, benzoyl peroxide, D-panthenol, octyl methoxycinnamate, titanium dioxide, octyl salicylate, homosalate, avobenzone, carotenoids, free radical scavengers, spin traps, amines, retinoids such as retinol and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogen, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper chloride, copper-containing peptides such as Cu:Gly-His-Lys, coenzyme Q10, peptides, amino acids such as proline, vitamins, lactobionic acid, acetyl-CoA, niacin, riboflavin, thiamine, ribose, electron transfer substances such as NADH and FADH2, and other plant extracts such as aloe, feverfew, oatmeal, and their derivatives and mixtures. The cosmetic active agent is generally present in an amount of about 0.001% to about 20%, for example about 0.005% to about 10%, such as about 0.01% to about 5%, by weight of the topical skin preparation of the present invention.
[0065] Examples of vitamins include, but are not limited to, vitamin A, vitamin B (e.g., vitamin B3, vitamin B5, and vitamin B12), vitamin C, vitamin K, and different forms of vitamin E (e.g., α, β, γ, or Δ tocopherol) or mixtures thereof and derivatives thereof.
[0066] Examples of hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid.
[0067] Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl-cysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbic acid polypeptide). Oil-soluble antioxidants suitable for use in the skin topical preparations of the present invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol ethyl ester), tocotrienols and ubiquinone. Natural extracts containing antioxidants suitable for use in the skin topical preparations of the present invention include, but are not limited to, extracts containing flavonoids and isoflavones and their derivatives (e.g., genistein and di-zein), extracts containing resveratrol, and the like. Examples of such natural extracts include grape seeds, green tea, pine bark, and propolis.
[0068] How to use
[0069] The skin preparation of the present invention can be topically applied to the skin of a mammal of one or more skins that need to be treated. In one embodiment, the skin preparation can be applied to the skin that needs to be treated for whitening, brightening, yellowing, and anti-aging. The skin preparation can be applied to the skin that needs such treatment according to a suitable treatment regimen, such as monthly, weekly, every other day, daily, twice a day, etc.
[0070] In certain embodiments, the skin topical preparations of the present invention can also be used to treat other needs related to the skin. For example, the skin topical preparations of the present invention can be used to treat hyperpigmentation after inflammation, to reduce pore size, to reduce sebum production, and to alleviate scars. In certain other embodiments, the skin topical preparations of the present invention can be applied simultaneously with a mechanical or physical epidermal exfoliation treatment (e.g., microdermabrasion treatment) or within a few hours of the treatment, or simultaneously with a chemical peel or keratolytic agent such as salicylic acid. In certain other embodiments, the skin topical preparations of the present invention can be applied to mucous membranes or other tissues such as vaginal tissue, oral tissue, or eye tissue. In certain other embodiments, the skin topical preparations of the present invention can be applied to mild wounds or postoperative sites to promote healing, to insect bites, to poison ivy skin disorders or similar skin conditions, or generally used to relieve itching.
[0071] The present invention is further described below in conjunction with specific examples. It is necessary to point out that the examples are only used to further illustrate the present invention and cannot be construed as limiting the scope of the present invention. Those skilled in the art can make some non-essential improvements and adjustments based on the content of the present invention described above. The test methods in the following examples that do not specify specific conditions are usually based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise stated, all percentages and parts are by weight.
[0072] The stigmasterane mixture used in the present invention has a purity of more than 90%, is derived from chamomile, and is provided by the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences.
[0073] Example 1: Sample preparation
[0074] Weigh 42.77 mg of the stigmasterane mixture, dissolve it with dimethyl sulfoxide (Sigma, DMSO), add an appropriate amount of DMSO and make up to 100 mL volumetric flask to obtain a 427.7 mg / L stigmasterane mixture solution for use.
[0075] Example 2: Sample preparation
[0076] In a biosafety cabinet, 10 μL of Example 1 was taken with a pipette, and an appropriate amount of cell culture medium (DMEM culture medium, Gibco) was added to 10 mL to obtain a 0.43 mg / L stigmasterane mixture cell culture medium for use.
[0077] Example 3: Sample preparation
[0078] In a biosafety cabinet, 50 μL of Example 1 was pipetted with a pipette, and an appropriate amount of cell culture medium (DMEM culture medium, Gibco) was added to 10 mL to obtain a 2.14 mg / L stigmasterane mixture cell culture medium for use.
[0079] Test Example 1: Anti-glycation effect test
[0080] 1. Test principle:
[0081] Glycation is a non-enzymatic chemical reaction. Proteins react with carbonyl compounds (glucose, fructose, glyoxal, etc.) to form a series of irreversible advanced glycation end products (AGEs). AGEs can cross-link with proteins to change the physiological activity of proteins and cause a series of pathological and physiological changes. These modifications affect both extracellular and intracellular proteins, leading to cell and tissue dysfunction, thereby accelerating the aging process of the skin. Carboxymethyl lysine (CML) is one of the representatives of advanced glycation end products. In the experiment, glyoxal was used to induce glycosylation in primary human skin fibroblasts, and immunofluorescence staining was used to quantitatively analyze the expression of CML.
[0082] This test was designed to evaluate the potential anti-glycation effects of a mixture of stigmasteranes in a cell model.
[0083] 2. Test materials:
[0084] 2.1 Main reagents:
[0085] Human primary dermal fibroblasts and culture medium were purchased from Cell Technology; penicillin-streptomycin-amphotericin B solution was purchased from Bioind, DPBS was purchased from Gibco, CCK reagent was purchased from Tongren Biotechnology (40203ES80); 96-well cell culture plates were purchased from Thermo; CML antibody was purchased from Abcam, Alexa 568Donkey Anti-Mouse IgG was purchased from Invitrogen, bovine serum albumin BSA was purchased from Beyotime, glyoxal was purchased from Adamas, and aminoguanidine (Aladdin, A151036) was purchased from Adamas.
[0086] 2.2 Main equipment:
[0087] Cell culture incubator, inverted fluorescence microscope (Leica), biological safety cabinet, and microplate reader.
[0088] 3. Test groups and concentrations:
[0089] Table 1
[0090]
[0091] 4. Test method:
[0092] 4.1 Cell seeding:
[0093] After digestion, the cells were inoculated into a 24-well plate with cell slides added, with 1.5*10 4 cells.
[0094] 4.2 Glycation induction:
[0095] After 48 hours, the cells were treated with 0.5 mM glyoxal to induce glycation reaction as a negative control group, and a blank group (NT) and a sample group (glyoxal + sample) were set up, and the cells were treated for 48 hours.
[0096] 4.3 Fixation and staining:
[0097] The induced cells were rinsed once with PBS, fixed with paraformaldehyde (PFA), and then CML fluorescent staining was performed. After BSA blocking, primary antibody incubation and secondary antibody incubation, the cells were finally sealed with an aqueous mounting medium containing DAPI. Fluorescence images were taken with a fluorescence microscope, and the images were quantitatively analyzed using Image J.
[0098] 3.3 Statistical methods
[0099] All results were expressed as Mean±SD.
[0100] 4. Experimental Results
[0101] The cells were treated with Example 2 and Example 3 and analyzed by fluorescence staining. Figure 3 and 4 Image analysis showed that the glycation inhibition rates of 0.43 mg / L and 2.14 mg / L stigmasterane mixtures were 33.00% and 39.00%, respectively. The detailed data of CML fluorescence image quantification are shown in Table 2.
[0102] Table 2
[0103]
[0104] The immunofluorescence experiment showed that compared with the control group, the stigmasterane mixture at concentrations of 0.43 mg / L and 2.14 mg / L could significantly inhibit AGEs, with inhibition rates of 33.00% and 39.00%, respectively, indicating that the anti-glycation effect of the stigmasterane mixture was more prominent.
[0105] The stigmasterane mixture of the present invention can be used as an intermediate raw material or an effective additive for the preparation of medicines, health foods, oral agents or skin topicals. The skin topicals are preferably cosmetic compositions, including but not limited to the preparation of products in the form of creams, emulsions, gels, lotions, essences, facial masks, eye creams, aerosols (cleansing bubbles), sprays, shower gels and facial cleansers. The weight percentage of the stigmasterane mixtures of Examples 1-6 in medicines, health foods, oral agents or skin topicals is 0.00001%-20% (w / w). The preferred weight percentage is 0.0001%-10% (w / w). The more preferred weight percentage is 0.0001%-5% (w / w). The most preferred weight percentage is 0.001%-5% (w / w).
[0106] The following are specific application examples of the stigmasterane mixture in medicines, health foods, oral preparations or skin topical preparations, as well as the formulations and preparation methods of these dosage forms. In the following tables, "-" means no addition.
[0107] Application Example 1: Preparation of facial cream
[0108]
[0109]
[0110] Application Example 2: Preparation of Emulsion
[0111]
[0112]
[0113] Application Example 3: Preparation of Gel
[0114]
[0115] Application Example 4: Preparation of lotion
[0116]
[0117]
[0118] Application Example 5: Preparation of Essence
[0119]
[0120] Application Example 6: Preparation of facial mask
[0121]
[0122] Application Example 7: Preparation of Eye Cream
[0123]
[0124]
[0125] Application Example 8: Preparation of Aerosol (Cleaning Bubble)
[0126]
[0127] Application Example 9: Preparation of Spray
[0128]
[0129]
[0130] Application Example 10: Preparation of Shower Gel
[0131]
[0132] Application Example 11: Preparation of facial cleanser
[0133]
[0134]
Claims
1. Anti-glycation application of stigmasterane mixture.
2. The use according to claim 1, It is characterized in that The stigmasterane mixture is used at a concentration of at least 0.5 mg / L.
3. The use according to claim 2, It is characterized in that The stigmasterane mixture is used at a concentration of at least 1 mg / L.
4. The use according to claim 1, It is characterized in that The anti-glycation is the end product of inhibiting non-enzymatic glycosylation reaction.
5. The use according to claim 1, It is characterized in that The anti-glycation is to inhibit the glycation end products.
6. Application of stigmasterane mixture in the preparation of skin external preparations, medicines and health foods with anti-glycation effects.
7. The use according to claim 6, It is characterized in that The content of the stigmasterane mixture in external skin preparations, medicines and health foods is 0.00005-10% by weight.
8. The use according to claim 7, It is characterized in that The content of the stigmasterane mixture in external skin preparations, medicines and health foods is 0.0001-5% by weight.
9. The use according to claim 6, It is characterized in that The skin external preparation is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.
10. The use according to claim 6, It is characterized in that The anti-glycation is the end product of inhibiting non-enzymatic glycosylation reaction.
11. The use according to claim 6, It is characterized in that The anti-glycation is to inhibit the glycation end products.
